SIRS-Lab launches VYOO, a novel DNA-based test for the detection of sepsis pathogens. Within 6 hours, key-information for a successful antibiotic therapy is provided. VYOO combines precision, short time-to-results, and easy handling.
With the specific and fast identification of bacteria, fungi, and resistances, VYOO carries significant potential to guide the antibiotic therapy in patients suffering from sepsis. The PCR based test detects 40 bacterial and fungal species that cause life-threatening infections. Simultaneously, 5 important antibiotic resistances are identified.
The results of 16 patients per user are provided within 6 hours whereby diagnostic key information is available within the first treatment cycle. International studies prove that the so called "golden hours" of sepsis treatment are crucial for the individual prognosis of the patient. Moreover, VYOO will contribute to dealing with the increasing public health problem of antibiotic resistances.
In microbiology laboratories, VYOO will be an effective system for the analysis of complex blood samples. The test works with standard PCR equipment and is easy to handle. Dr. Marc Lehmann, SIRS-Labs chief developer, remarks: "First retrospective studies will be presented to international experts at the congress 'Sepsis and Multiorgan Dysfunction' on September 6, 2007 in Weimar, Germany. These data document an increased hit-rate and dramatically reduced time-to-result as well as proved ease of use."
The high sensitivity of VYOO is achieved by LOOXSTER®, which is based on SIRS-Labs proprietary PUREPROVE® technology for the enrichment of bacterial and fungal DNA. In a multiyear process and in close collaboration with leading clinicians and microbiologists, SIRS-Lab GmbH have developed VYOO ready for the market.